Clinical

Higher social vulnerability was associated with lower dietary fiber intake and a hostile gut microbiome in patients with melanoma or sarcoma receiving immune checkpoint blockade.

GLP-1s and SGLT2s were associated with improved kidney outcomes and no increased safety risks in patients with T1D and CKD.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

Racial gaps in curative treatment for early-stage NSCLC persist among Medicare beneficiaries, with Black patients less likely to receive surgery.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.

Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.

Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer inpatients to community dental providers.

Researchers find that epigenetic changes from the famine caused CV and mental health effects for 3 to 4 generations on both sides of the Atlantic.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

Racial and geographic CRC disparities described in a recent report highlight the need for urgent research and prevention efforts nationwide.

The results are the latest from the multiarm EPCORE-NHL-2 trial, which has studied the bispecific antibody epcoritamab in multiple uses and combinations.

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and emerging outcome measures.

Persistent high-level EBNA-1 peptide antibody titers could be used to identify multiple sclerosis (MS) vs neuromyelitis optica spectrum disorder (NMOSD).

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

The efficacy and safety of efgartigimod in pediatric patients will need to be further validated with future studies.

Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ibrutinib among BTK inhibitors.

Federal RHTP funding often misses states with the highest rural mortality and greatest projected Medicaid funding losses, researchers found.

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd Schlesinger, MD.